In one study, after 6 months of treatment with MSDC-0602 K, individuals showed a significant reduction in glucose, HbA1c, insulin, liver enzymes and improved liver histology (NAS score [NAFLD activity score]) but no improvement in fibrosis, when compared with placebo [15]. Here, INS is linked to metabolic dysfunction-associated steatotic liver disease.